Clinical Trial

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Study acronym: TOMATO
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-10; most recent amendment 2026-01-07.
Status change: Recruiting → Active, Not Recruiting 2026-01-07
Status change: Not Yet Recruiting → Recruiting 2024-07-08
Trial Details
NCT Number NCT06452537
Lead Sponsor Tianjin Medical University General Hospital
Conditions Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Enrollment 102 participants
Start Date 2024-07-09
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-08